Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donidalorsen in Pediatric Patients Age 2 to Less Than 12 Years Old With Hereditary Angioedema
NCT07298447Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 3 trial of donidalorsen in hereditary angioedema (HAE), sponsored by Ionis Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT07298447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298447.